Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in T2DM on Metformin
NCT00900146Phase 3Terminated
- Sponsor
- Novartis
- Start
- Apr 2009
- Primary completion
- Nov 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of canakinumab in type 2 diabetes mellitus (T2DM), sponsored by Novartis. Started Apr 2009; status: terminated.
02
Drugs
canakinumab
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00900146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00900146.